Deramiocel Shows Positive Phase 3 Results for Duchenne Muscular Dystrophy

The Lancet has published final one-year results from Capricor Therapeutics' Phase 3 HOPE-3 trial for Deramiocel, an investigational cell therapy for Duchenne muscular dystrophy. The study met its primary endpoint, demonstrating a 54% reduction in upper limb function decline and indicating cardiac benefits. This development is significant as the Biologics License Application for Deramiocel is currently under FDA review, potentially offering a new treatment option for DMD patients.